Pomerantz Law Firm Issues Warning About Class Action Lawsuit for Pacira Biosciences Investors

Investor Alert: Class Action Lawsuit Against Pacira Biosciences

Pomerantz LLP has officially announced the initiation of a class action lawsuit targeting Pacira Biosciences, Inc., a biopharmaceutical company listed on NASDAQ under the ticker symbol PCRX. This legal action is prompted by alleged fraudulent activities or other improper business practices conducted by Pacira and certain of its executives or directors.

For investors who have lost money in their investment with Pacira, the law firm encourages them to reach out to Danielle Peyton, a representative of the firm, at [email protected] or via phone at 646-581-9980. Interested parties may also contact the firm toll-free at 888.4-POMLAW, with an extension to speak directly with Peyton.

The class period under scrutiny allows affected investors until March 14, 2025, to request to be appointed as Lead Plaintiff in the case, assuming they acquired Pacira's securities during the designated timeframe. To obtain a copy of the filed complaint, parties can visit the Pomerantz Law Firm's official website.

Background of the Lawsuit

On August 9, 2024, Pacira faced significant setbacks when a patent infringement lawsuit against eVenus Pharmaceutical Laboratories, Inc. led to the invalidation of its '495 patent. This patent pertains to Exparel, Pacira's non-opioid pain management solution, which the court ruled was based on evident prior techniques and concepts. This ruling resulted in a considerable decline in Pacira's stock price, which plummeted by 47.67% or $10.66 per share, closing at $11.70 on the day of the announcement.

The Pomerantz Law Firm has a longstanding reputation in corporate law, particularly in representing clients in issues related to securities, antitrust, and class action lawsuits. Established by Abraham L. Pomerantz more than 85 years ago, the firm has made considerable strides in advocating for victims of securities fraud, unsafe corporate practices, and breaches of fiduciary duty. The firm has historically secured various multimillion-dollar settlements for class members and continues to uphold its mission of justice for those affected by corporate malpractice.

Conclusion and Next Steps

Affected investors are highly encouraged to act swiftly in contacting the firm to discuss potential claims and options available to them. As the case develops, keeping abreast of updates will be crucial for all stakeholders involved with Pacira Biosciences.

For additional information or inquiries, please refer to the Pomerantz Law Firm's website or contact their office directly via the provided communication channels. Stay informed about your rights and options as the legal proceedings unfold.